|
| Study, year | Disease | Outcome | Administration |
|
| Maier et al., 2000 [13] | Ischemia reperfusion injury | Prevents endothelial dysfunction | 6R-BH4 (Alexis Corp.) intracoronary 10−2 M, for 2 min |
| Setoguchi et al., 2001 [22] | Coronary artery disease | Improves endothelium-dependent vasodilatation | 6R-BH4 (Clinalfa) intracoronary infusion 4 mg/min for 2 min |
| Nyström et al., 2004 [23] | Type 2 diabetic and coronary heart disease | Had no effect on endothelial-dependent vasodilation | 6R-BH4 (Schircks) intra-arterial infusion 500 g/min |
| Worthley et al., 2007 [24] | Atherosclerotic disease | Does not improve endothelial function | 6R-BH4 (Clinalfa) infusion 250 μg/min and 500 μg/min for 6 min |
| Settergren et al., 2009 [25] | Diabetes (type II) and coronary artery disease | Improves endothelial dysfunction | 6R-BH4 (Clinalfa) intra-arterial infusion 500 μg/min |
| Cunnington et al., 2012 [26] | Coronary artery disease | Has no net effect on vascular redox state or endothelial function | 6R-BH4 (Schircks) 400 mg/d or 700 mg/d per oral for 2 to 6 weeks |
| Stroes et al., 1997 [27] | Hypercholesterolemia | Restored NO-dependent vasodilatation | 6R-BH4 (Alexis Corp.) infusion 500 μg/min |
| Fukuda et al., 2002 [30] | Hypercholesterolemia | Improves coronary endothelial function | 6R-BH4 (Sigma) intracoronary 1 mg/min for 2 min |
| Wyss et al., 2005 [28] | Hypercholesterolemia | Restores flow reserve utilization | 6R-BH4 (Schircks) infusion 10 mg kg−1
over 30 min |
| Holowatz and Kenney, 2011 [29] | Hypercholesterolemia | Augmented NO-dependent vasodilatation | 6R-BH4 (Sigma) 10 mM |
| Cosentino et al., 2008 [14] | Hypercholesterolemia | Restores NO bioavailability and endothelial function | 6R-BH4 (Schircks) 400 mg twice daily orally for 4 weeks |
| Higashi et al., 2002 [31] | Hypertension | Augments endothelium-dependent vasodilatation | 6R-BH4 (Sigma) infusion 500 μg/min |
| Porkert et al., 2008 [12] | Hypertension | Significant improvement in endothelial function in higher doses | 6R-BH4 (Schircks) oral 5/10 mg kg−1 day for 8 weeks and 200/400 mg for 4 weeks |
| Heitzer et al., 2000 [15] | Diabetes (type II) | Improves endothelium-dependent vasodilatation | 6R-BH4 (Schircks) intra-arterial infusion 500 μg/min |
|
